The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CGON | +129.27% | N/A | N/A | +66% |
| S&P | +17.45% | +75.43% | +11.88% | +38% |
CG Oncology, Inc. is a clinical biopharmaceutical company, which engages in the development and commercialization of bladder-sparing therapeutic for patients afflicted with bladder cancer. It offers cretostimogene, a product initially in clinical development for the treatment of patients with Non-Muscle Invasive Bladder Cancer (NMIBC). The company was founded by Alex Yeung and Paul DeRidder on September 24, 2010 and is headquartered in Irvine, CA.
This clinical-stage biotech develops bladder-sparing therapies for high-risk cancer patients with limited treatment options.
One pundit believes this is a clinical-stage company well worth watching.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $2.32M | 409.2% |
| Gross Profit | -$797.00K | 0.0% |
| Gross Margin | -34.32% | 0.0% |
| Market Cap | $3.35B | 72.7% |
| Market Cap / Employee | $23.59M | 0.0% |
| Employees | 142 | 25.7% |
| Net Income | -$41,309.00K | -29.9% |
| EBITDA | -$47,851.00K | -25.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $32.49M | -87.4% |
| Accounts Receivable | $688.00K | 0.0% |
| Inventory | 1.6 | 0.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $6.11M | 11642.3% |
| Short Term Debt | $915.00K | 391.9% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -20.82% | -2.4% |
| Return On Invested Capital | -22.35% | 3.4% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$36,223.00K | -73.6% |
| Operating Free Cash Flow | -$36,216.00K | -75.3% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 2.54 | 2.81 | 4.58 | 4.73 | 30.98% |
| Price to Sales | 2818.48 | 3596.91 | 1421.65 | 823.19 | -57.07% |
| Price to Tangible Book Value | 2.54 | 2.81 | 4.58 | 4.83 | 33.79% |
| Enterprise Value to EBITDA | -27.94 | -27.21 | -47.67 | -54.14 | 42.82% |
| Return on Equity | -16.6% | -21.0% | -24.7% | -21.7% | 12.99% |
| Total Debt | $1.04M | $994.00K | $7.24M | $7.02M | 2850.00% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
